Spinout Active LTD

Company profile

Gitlife Biotech Ltd

Home - GitLife Biotech

We will set the global standard in the management of provenance and integrity for biological assets; enabling the potential of synthetic biology to be realised worldwide.

CRN
14690170
Founded
2023
Age
3

Overview

Browse spinouts
Legal name
GITLIFE BIOTECH LTD
Region
North East England
Registered address
3RD FLOOR MAYBROOK HOUSE
27-35 GRAINGER STREET
NEWCASTLE UPON TYNE
UNITED KINGDOM
NE1 5JE
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Gitlife Biotech Ltd
CRN 14690170
2
Direct and ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

7 events
28 May
2027

Accounts due

Accounts Due

Next accounts due date

19 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

28 Aug
2025

Accounts filed

Accounts

Last accounts made up date

05 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

02 Oct
2024

Accounts With Accounts Type Total Exemption Full

Accounts Awaiting analysis

AA | Transaction MzQzODA5ODg4M2FkaXF6a2N4

Published 07 Oct 2024 11:13

02 Oct
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzODEzODUwNWFkaXF6a2N4

Published 02 Oct 2024 12:31

27 Feb
2023

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

GitLife Biotech develops DNA-based biosecurity tools and a version control system for synthetic biology using DNA barcoding.

The company set the global standard in the management of provenance and integrity for biological assets, enabling the potential of synthetic biology to be realised worldwide. It accomplishes this by setting the international standard for version control and biological asset integrity while enabling collaboration between governmental, commercial, academic and NGO entities.

Project impact

The company only started trading in 2023.

GitLife Biotech
2023
GitLife Biotech
2023
GITLIFE BIOTECH LTD
2023

Public funding

3 awards
First funded
2023
Funded years
2023, 2024
Age at first award
0 years

Projects

2024 Collaborative R&D Lead participant

TRACE (Tracking and Recording Accurate Cellular Engineering): Ensuring Provenance in ML-Driven Yeast Optimization

1 Feb 2024 to 31 Mar 2025

Awarded
£169,191
Total cost £241,701

Synthetic biology (SynBio) is a young and exciting field that combines many different scientific disciplines to redesign organisms for useful purposes by engineering them to perform new functions. SynBio has potential to revolutionise many existing industries and resolve crises in agriculture, energy and healthcare. There is no surprise that substantial f...

2024 Collaborative R&D

Harnessing the power of engineering biology to develop and translate novel live biotherapeutics

1 Feb 2024 to 31 Jan 2025

Awarded
£92,553
Total cost £132,218

In this exciting collaborative project, NCIMB, an established Scottish biotechnology company, is teaming up with GitLife Biotech (GLB), a spinout from Newcastle University. The partners aim to develop new innovative products and services using groundbreaking Engineering Biology protocols. The proposed project centres around the development of a new class ...

2023 Investment Accelerator Lead participant

GitLife 2.0: Utilising next generation digital technologies to deliver twenty-fold improvement to a unique version control system, enabling SynBio innovations in net zero and healthcare.

1 Nov 2023 to 30 Apr 2025

Awarded
£249,340
Total cost £361,363

Synthetic Biology (SynBio) is the application of engineering principles to biology. Synthetic Biologists think of proteins as machines, composed of multiple different components, each encoded by genes or parts of genes. By rearranging genes, they can make proteins with new functions. SynBio also uses computer modelling heavily, mapping what genes should g...

Product types

Collaborative R&D Investment Accelerator